162 related articles for article (PubMed ID: 26684028)
1. Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma.
Li K; Pan X; Bi Y; Xu W; Chen C; Gao H; Shi B; Jiang H; Yang S; Jiang L; Li Z
Oncotarget; 2016 Jan; 7(3):2496-507. PubMed ID: 26684028
[TBL] [Abstract][Full Text] [Related]
2. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
Chen C; Li K; Jiang H; Song F; Gao H; Pan X; Shi B; Bi Y; Wang H; Wang H; Li Z
Cancer Immunol Immunother; 2017 Apr; 66(4):475-489. PubMed ID: 28035433
[TBL] [Abstract][Full Text] [Related]
3. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.
Li D; Li N; Zhang YF; Fu H; Feng M; Schneider D; Su L; Wu X; Zhou J; Mackay S; Kramer J; Duan Z; Yang H; Kolluri A; Hummer AM; Torres MB; Zhu H; Hall MD; Luo X; Chen J; Wang Q; Abate-Daga D; Dropulic B; Hewitt SM; Orentas RJ; Greten TF; Ho M
Gastroenterology; 2020 Jun; 158(8):2250-2265.e20. PubMed ID: 32060001
[TBL] [Abstract][Full Text] [Related]
4. Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein.
Pan Z; Di S; Shi B; Jiang H; Shi Z; Liu Y; Wang Y; Luo H; Yu M; Wu X; Li Z
Cancer Immunol Immunother; 2018 Oct; 67(10):1621-1634. PubMed ID: 30078052
[TBL] [Abstract][Full Text] [Related]
5. Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma.
Batra SA; Rathi P; Guo L; Courtney AN; Fleurence J; Balzeau J; Shaik RS; Nguyen TP; Wu MF; Bulsara S; Mamonkin M; Metelitsa LS; Heczey A
Cancer Immunol Res; 2020 Mar; 8(3):309-320. PubMed ID: 31953246
[TBL] [Abstract][Full Text] [Related]
6. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma.
Sun L; Gao F; Gao Z; Ao L; Li N; Ma S; Jia M; Li N; Lu P; Sun B; Ho M; Jia S; Ding T; Gao W
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833049
[TBL] [Abstract][Full Text] [Related]
7. HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody.
Wang W; Nishioka Y; Ozaki S; Jalili A; Abe S; Kakiuchi S; Kishuku M; Minakuchi K; Matsumoto T; Sone S
Cancer Immunol Immunother; 2009 Jun; 58(6):967-76. PubMed ID: 18979097
[TBL] [Abstract][Full Text] [Related]
8. Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy.
Hai J; Zhang H; Zhou J; Wu Z; Chen T; Papadopoulos E; Dowling CM; Pyon V; Pan Y; Liu JB; Bronson RT; Silver H; Lizotte PH; Deng J; Campbell JD; Sholl LM; Ng C; Tsao MS; Thakurdin C; Bass AJ; Wong KK
Clin Cancer Res; 2020 Jul; 26(13):3431-3442. PubMed ID: 32209571
[TBL] [Abstract][Full Text] [Related]
9. Anlotinib enhances the antitumor activity of radiofrequency ablation on lung squamous cell carcinoma.
Zhou W; Gao Y; Tong Y; Wu Q; Zhou Y; Li Y
Pharmacol Res; 2021 Feb; 164():105392. PubMed ID: 33348023
[TBL] [Abstract][Full Text] [Related]
10. Administration of a glypican-3 peptide increases the infiltration and cytotoxicity of CD8
Zhao J; Qin L; He G; Xie T; Hu G; Wang F; Zhong H; Zhu J; Xu Y
Cancer Med; 2023 Dec; 12(23):21293-21307. PubMed ID: 37986544
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers.
Steffin D; Ghatwai N; Montalbano A; Rathi P; Courtney AN; Arnett AB; Fleurence J; Sweidan R; Wang T; Zhang H; Masand P; Maris JM; Martinez D; Pogoriler J; Varadarajan N; Thakkar SG; Lyon D; Lapteva N; Mei Z; Patel K; Lopez-Terrada D; Ramos C; Lulla P; Armaghany T; Grilley BJ; Dotti G; Metelitsa LS; Heslop HE; Brenner MK; Sumazin P; Heczey A
Res Sq; 2024 Apr; ():. PubMed ID: 38645165
[TBL] [Abstract][Full Text] [Related]
12. Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma.
Jiang Z; Jiang X; Chen S; Lai Y; Wei X; Li B; Lin S; Wang S; Wu Q; Liang Q; Liu Q; Peng M; Yu F; Weng J; Du X; Pei D; Liu P; Yao Y; Xue P; Li P
Front Immunol; 2016; 7():690. PubMed ID: 28123387
[TBL] [Abstract][Full Text] [Related]
13. Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.
Li W; Guo L; Rathi P; Marinova E; Gao X; Wu MF; Liu H; Dotti G; Gottschalk S; Metelitsa LS; Heczey A
Hum Gene Ther; 2017 May; 28(5):437-448. PubMed ID: 27530312
[TBL] [Abstract][Full Text] [Related]
14. Versatile strategy for controlling the specificity and activity of engineered T cells.
Ma JS; Kim JY; Kazane SA; Choi SH; Yun HY; Kim MS; Rodgers DT; Pugh HM; Singer O; Sun SB; Fonslow BR; Kochenderfer JN; Wright TM; Schultz PG; Young TS; Kim CH; Cao Y
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E450-8. PubMed ID: 26759368
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors.
Karlsson H; Svensson E; Gigg C; Jarvius M; Olsson-Strömberg U; Savoldo B; Dotti G; Loskog A
PLoS One; 2015; 10(12):e0144787. PubMed ID: 26700307
[TBL] [Abstract][Full Text] [Related]
16. T lymphocytes engineered to express a CD16-chimeric antigen receptor redirect T-cell immune responses against immunoglobulin G-opsonized target cells.
D'Aloia MM; Caratelli S; Palumbo C; Battella S; Arriga R; Lauro D; Palmieri G; Sconocchia G; Alimandi M
Cytotherapy; 2016 Feb; 18(2):278-90. PubMed ID: 26705740
[TBL] [Abstract][Full Text] [Related]
17. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.
Rodgers DT; Mazagova M; Hampton EN; Cao Y; Ramadoss NS; Hardy IR; Schulman A; Du J; Wang F; Singer O; Ma J; Nunez V; Shen J; Woods AK; Wright TM; Schultz PG; Kim CH; Young TS
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E459-68. PubMed ID: 26759369
[TBL] [Abstract][Full Text] [Related]
18. Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.
Harris DT; Kranz DM
Trends Pharmacol Sci; 2016 Mar; 37(3):220-230. PubMed ID: 26705086
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor-redirected T cells return to the bench.
Geldres C; Savoldo B; Dotti G
Semin Immunol; 2016 Feb; 28(1):3-9. PubMed ID: 26797495
[TBL] [Abstract][Full Text] [Related]
20. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.
Sanchez-Paulete AR; Labiano S; Rodriguez-Ruiz ME; Azpilikueta A; Etxeberria I; Bolaños E; Lang V; Rodriguez M; Aznar MA; Jure-Kunkel M; Melero I
Eur J Immunol; 2016 Mar; 46(3):513-22. PubMed ID: 26773716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]